Infusion centers are valued on EBITDA multiples that reflect drug mix profitability, payer contract quality, physician referral diversity, accreditation status, patient volume trends, and operational efficiency. EBITDA, or earnings before interest, taxes, depreciation, and amortization, measures the center's annual operating profit from providing infusion therapy services in an outpatient setting. The 6x to 11x EBITDA range spans routine hydration-focused centers at the low end and specialty biologics operations with diversified referral networks and strong commercial payer contracts at the top.

Adjusted EBITDA for an infusion center normalizes owner compensation and non-recurring items. A center generating $4.5M annual revenue with 55% in drug costs, 18% in nursing labor, 5% in facility costs, and 8% in administrative overhead produces roughly $630K EBITDA at a 14% margin. Adding back above-market physician-owner compensation brings adjusted EBITDA to $780K-$850K. At 8x EBITDA the center values at $6.2M-$6.8M. A comparable center with 45% specialty biologic revenue, favorable commercial payer contracts, 18 referring physicians, and ACHC accreditation might command 10x, or $7.8M-$8.5M — drug mix and referral diversity alone create a $1.6M-$1.7M valuation difference.

Drug mix composition is the primary margin driver in infusion center valuation. Specialty biologics and biosimilars for autoimmune conditions, neurological disorders, and rare diseases generate $3,000-15,000 per infusion with drug margins of 15-30% depending on payer contracts and group purchasing organization membership. Routine IV hydration and antibiotic infusions generate $200-800 per visit at lower margins but with higher patient throughput. Centers generating 40-plus percent of revenue from specialty biologics achieve EBITDA margins substantially above hydration-focused operations because per-visit revenue and margins are both higher. Buyers analyze drug mix by therapy category, evaluating reimbursement trends, biosimilar competition exposure, manufacturer rebate programs, and pipeline drugs entering the infusion market. Limited Distribution Drug programs and specialty pharmacy partnerships that provide access to high-margin restricted therapies create competitive advantages that command premium multiples.

Payer contract quality directly determines revenue per infusion visit and margin sustainability. Commercial payer contracts typically reimburse professional service fees at 120-180% of Medicare rates, with drug reimbursement structured as ASP-plus-percentage or AWP-minus-percentage formulas. Centers with commercial payer contracts representing 40-plus percent of patient mix achieve blended reimbursement rates 30-50% above Medicare-dependent operations. Contract terms, renewal cycles, and historical rate trends indicate pricing power or compression pressure. In-network status with all major regional commercial payers provides patient access and eliminates balance billing barriers that limit out-of-network facilities. Buyers model payer mix by patient volume and per-visit reimbursement, projecting forward EBITDA under various contract renewal scenarios.

Physician referral diversity across specialties and individual physicians provides the patient pipeline stability essential to sustaining and growing infusion volume. Centers receiving referrals from 15-plus actively referring physicians across rheumatology, gastroenterology, neurology, oncology, and primary care demonstrate diversified patient acquisition channels resistant to any single referral source disruption. Concentration where one or two physicians account for 50-plus percent of referrals creates existential risk — physician retirement, relocation, or changed referral patterns immediately impact patient volume. Buyers analyze referral data by physician, specialty, diagnosis, and monthly volume trends to model pipeline sustainability. Formalized referral relationships through preferred provider arrangements or value-based care agreements demonstrate deeper physician engagement than informal patterns.

Accreditation status from ACHC or URAC provides both operational credibility and practical market access. Accredited centers qualify for payer network inclusion and specialty pharmacy partnerships that non-accredited facilities cannot access, directly impacting patient volume and drug availability. The accreditation process requires documented quality management systems, infection control protocols, staff competency verification, and patient safety programs. Centers maintaining continuous accreditation through multiple three-year survey cycles demonstrate sustained operational discipline. National platform buyers like Option Care Health and health system acquirers require accreditation as a baseline criterion because their payer contracts and operational standards mandate accredited sites.

Patient volume trends over 12-24 months indicate market momentum and growth potential. Centers showing 10-plus percent annual infusion visit growth demonstrate expanding referral networks and market penetration that buyers project forward in their EBITDA models. Flat or declining volume raises concerns about market saturation, competitive pressure, or referral pipeline weakness. Chair utilization of 70-plus percent indicates demand approaching capacity, which represents both revenue optimization and potential expansion opportunity. Centers operating below 50% utilization signal either recent startup phase or concerning demand weakness that requires investigation.

Operational efficiency determines EBITDA conversion from revenue. Nursing productivity measured by infusions per nursing hour, drug waste percentage below 3%, scheduling optimization that maximizes chair utilization, and overhead costs below 15% of revenue indicate well-managed operations. Inefficient centers represent EBITDA improvement opportunities: buyers from platform backgrounds identify 200-400 basis points of margin expansion potential through operational improvements including group purchasing, staffing optimization, and scheduling technology.

The buyer landscape includes national infusion platforms like Option Care Health and Orsini paying 8x-11x EBITDA for accredited centers with specialty drug programs and geographic fill-in value, PE firms building ambulatory infusion networks at 7x-9x, health systems acquiring outpatient infusion capacity at 6x-8x, and specialty pharmacy companies securing patient access points at 7x-10x. National platforms pay top multiples for centers that add geographic coverage to their existing payer contracts and drug access programs.